Data from these three Phase 2 studies of VX-150, together with initial Phase 1 and 2 data for VX-128 and Phase 1 data for the intravenous dosing study of VX-150, will inform future development ...

Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and ...

Vertex will open a new stage of its search for the perfect NaV1.8 inhibitor when it moves another of VX-150’s siblings into phase 1 later in the first half of 2020.

Vertex Pharmaceuticals Incorporated VRTX announced positive results from a phase II study evaluating its NaV1.8 inhibitor VX-150 in patients suffering from pain caused by small fiber neuropathy ...

Vertex Pharma now has a pair of studies backing up its new drug VX-150, suggesting it can provide opioidlike pain relief without the addiction risks. The positive phase 2 data comes right on the ...

Vertex Standard LMR, Inc., a leading manufacturer of two-way radios, today announced an enhanced version of its VX-260 analog series of radios, providing a greater array of features ...

Vertex’s treatment, called VX-150, showed promise in a study on 124 patients with knee pain caused by osteoarthritis, significantly improving symptoms compared with placebo, the company said ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results of a Phase 2 study of the NaV1.8 inhibitor VX-150 in patients with acute pain following bunionectomy surgery.